{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"CR is defined as a complete resolution of all target lesions by CT scans with complete normalization of FDG-PET uptake in all areas, and bone marrow biopsy negativity.","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nIpilimumab: Given IV\n\nLenalidomide: Given PO","id":"OG000","title":"Autologous -Treatment (Lenalidomide and Ipilimumab)"},{"description":"Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nIpilimumab: Given IV\n\nLenalidomide: Given PO","id":"OG001","title":"Allogeneic - Treatment (Lenalidomide and Ipilimumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days following the last dose of study drug","title":"Number of Participants Achieved Complete Remission","type":"SECONDARY","unitOfMeasure":"Participants"}